Trial Profile
Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Alfa-2b Treatment to Increase Sustained Response in HBeAg-positive Chronic Hepatitis B (PEGON-study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Nucleosides; Nucleotides
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms PEGON
- 01 Feb 2019 Results of post hoc analysis of two international RCTs (NCT00877760 and NCT01532843) published in the Alimentary Pharmacology and Therapeutics
- 17 Mar 2017 Primary endpoint (Sustained response) has not been met.
- 17 Mar 2017 Primary endpoint (Response at week 96) has not been met.